Objective: To evaluate the influence of cardiac arrestÀresuscitated donors (CARDs) on the outcome of heart recipients.
Recipient survival according to history of cardiac arrest in donors.
Central Message
History of cardiac arrest in donors with a preserved left ventricular ejection fraction at time of organ procurement doesn't affect outcome of heart recipients.
Perspective
The use of donors with history of cardiac arrest is safe and may increase donors' pool and reduce the gap between the growing number of recipients waiting for heart transplant and the ongoing organ shortage. The evidence that short period of ischemia due to cardiac arrest does not affect heart recipients outcome is an essential premise to perform heart transplant from non heart beating donors.
See Editorial Commentary page 631.
Heart transplantation represents the treatment of choice for patients with end-stage heart failure, providing improved quality of life and survival in these patients 1 ; unfortunately not all patients can benefit from heart transplantation because of an organ donor shortage, which results in a mortality rate while on a waiting list that ranges from 12% up to 19% in greater-risk patients. 2 One strategy to implement the limited organ availability is to expand criteria for acceptance of organ donors 3 ; however, reluctance exists in accepting organs for transplantation from donors who sustained a cardiac arrest because of the concern that warm ischemic injury could negatively influence graft and patient survival. Recent studies showed that history of cardiac arrest resuscitation in donors is not associated with negative outcome in heart recipients [4] [5] [6] or in other solid-organ recipients. 7, 8 In this study, we sought to evaluate the impact of cardiac arrest resuscitated donors on heart recipients' early and late outcome.
PATIENTS AND METHODS Study Population
The study protocol was approved by the institutional review board. Clinical records of all adult patients who underwent transplantation between July 2004 (when national high urgency inscription list was established in France) and December 2012 were reviewed retrospectively. Patients undergoing multiorgan and retransplantation were excluded from the study. Data were collected until June 2014. Patients were divided into 2 groups according to the history of cardiac arrestÀresuscitated donors (CARDs), named respectively CARDþ and CARDÀ group. Clinical records of donors were provided by the Agence de la Biomedicine, the French Agency for organ transplantation that guarantees for the accurateness of the information.
Operative Technique
Grafts were harvested from beating-heart brain-dead donors, preserved with the use of Celsior cardioplegic solution (IMTX Sangstat, Lyon, France), and stored in cold saline solution during transportation. Heart transplantation was performed according to the bicaval technique; to protect donor heart during implant, we used cold blood cardioplegia, and we performed all anastomoses with single aortic crossclamping (Video 1).
Immunosuppression
All patients received immunosuppressive treatment consisting of antilymphocyte globulin (Thymoglobulin; Genzyme Transplant, Cambridge, Mass) at a dose of 1.5 mg/kg/day for the first 5 postoperative days and preoperative intravenous methylprednisolone and mycophenolate mofetil. Postoperatively, patients received cyclosporin 4 to 6 mg/kg/day (target level 300 ng/mL), mycophenolate mofetil 2 g/day, and prednisone 1 mg/kg/day, which was reduced progressively to 0.2 mg/kg/day. Minimization of immunosupression by lower levels of calcineurin inhibitor (adapted for serum level of 50-100 ng/mL) and corticosteroids (5-10 mg/day) was common practice and safe in this population.
Patients' regimens were modified during follow-up visits and switched to tacrolimus, sirolimus, or everolimus as appropriate (acute allograft rejection, cardiac allograft vasculopathy, malignancies). High-dose corticosteroid was the first-line therapy for acute cellular allograft rejection with grade more than 1R. Since 2008, the detection of pretransplant and posttransplant donor-specific anti-human leukocyte antigen (HLA) antibodies has been based on Luminex mixed class I and II Antibody Screening kits (One Lambda, Canoga Park, Calif); patients with a positive screen were characterized for HLA class I and/or class II antibody specificity with LABScreen Single Antigen beads (One Lambda, Canoga Park, Calif). Pretransplant as well as posttransplant plasmapheresis was performed in HLA-immunosensitized patients transplanted with donor-specific anti-HLA antibodies.
Follow-up
Patients were followed closely and received routine laboratory tests, clinical examination, echocardiography, endomyocardial biopsy (EMB), and coronary angiography according to our institutional protocols. Patients were monitored by repetitive EMBs to detect allograft rejection; EMBs were performed approximately 10 to 15 times during the first year posttransplant, 3 times during the second year, and twice a year from the third to the tenth year. Coronary angiography was performed every 2 years; in presence of cardiac allograft vasculopathy (CAV), coronary angiography was performed every year and in case of coronary angioplasty and stenting, a control angiography was performed 6 months after the procedure. The following posttransplant events were recorded for all patients: number and grade of acute cellular allograft rejection episode and the presence and grade of CAV defined according to The International Society for Heart & Lung Transplantation classifications. 9, 10 Data were collected until the end of June 2014.
Statistical Analysis
Categorical variables are expressed as number and percentages and were compared with c 2 test. Continuous variables are expressed as the mean AE 1 standard deviation and compared with the Student t test, and continuous variables with a skewed distribution are presented as median and interquartile range and compared with Mann-Whitney U test. The Kaplan-Meier method was used to draw survival curves and calculate 30-day, 1-, 5-, and 10-year survival, and the log-rank test was used to compare survival among groups. Hazard ratios for mortality were determined by univariable and multivariable Cox proportional hazards regression analysis with data presented as hazard ratio with 95% confidence intervals. A 2-tailed P value of less than .05 was taken to indicate statistical significance. Statistical analysis was performed with SPSS 17.0 statistical software (SPSS Inc, Chicago, Ill).
RESULTS
From July 2004 to December 2012, a total of 625 heart transplantations were performed at our institution; 28 patients underwent multiorgan transplantation and 13 patients underwent retransplantation and were excluded from the study. One hundred seventeen recipients received VIDEO 1. A crucial moment during the cardiac transplantation: after de-airing, the aortic crossclamp is removed and the cardiac activity restarts. Video available at: http://www.jtcvsonline.org/article/S0022-5223 (16) Tables 1 and 2 , respectively. Of note, donors who sustained a cardiac arrest were significantly younger than donors who did not (44 [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] .1] days; P ¼ .344). The 2 recipients groups were similar for age, sex, national high urgency inscription list, need for preoperative extracorporeal membrane oxygenation (ECMO), etiology of cardiomyopathy, and redo surgery; of note, recipients of the CARDþ group had significantly more left ventricular assist device (LVAD) use compared with recipients of the CARDÀ group (10% vs 4%; P ¼ .007); however, there was no difference in the duration of LVAD support between the 2 groups (363 AE 183 vs 392 AE 189 days; P ¼ .69).
No difference was observed between the 2 groups with respect to ischemic time, need for postoperative ECMO for primary graft failure (PGF), or other early postoperative complications ( Table 2) . Donors of recipients who needed a postoperative ECMO (n ¼ 177, 30%) had similar troponin T peak levels CARD, Cardiac arrestÀresuscitated donor; ECMO, extracorporeal membrane oxygenation; LVAD, left ventricular assist device; BIVAD, biventricular assist device; TAH, total artificial heart; CPB, cardiopulmonary bypass.
FIGURE 1.
Plot showing relationship between serum troponin T peak levels (ng/mL) and cardiac arrest duration (minutes). 
Recipient Survival
At the end of the follow-up, a total of 223 events were recorded, including 221 deaths and 2 retransplantations; in particular, we recorded 32 events in the CARDþ group, including 31 deaths and 1 retransplantation for primary graft dysfunction and 191 events in the CARDÀ group, including 190 deaths and 1 retransplantation for chronic allograft rejection. The median follow up was 4.7 years [7.4-3.2] in the CARDþ group and 5.6 [7.8-3.4] years in the CARDÀ group (P ¼ .016). Kaplan-Meier analysis showed a mean survival time of 6.8 AE 0.3 and 6.1 AE 0.2 years in the CARDþ group and in the CARDÀ group, respectively. There was no difference in 30-day and 1-year mortality between the 2 groups; the survival rates were 89.7% at 30 days and 77.8% at 1 year in the CARDþ group and 83.3% at 30 days and 71.9% at 1 year in the CARD-group. At 5 years and at 10 years, however, CARDÀ patients showed a significantly lower survival rate compared with CARDþ patients: 61.3% versus 73.8% (P ¼ .032), respectively, at 5 years and 50.4% versus 69.4% respectively (P ¼ .017) at 10 years ( Figure 2 ). The main causes of 30-day and late mortality are listened in Table 3 . No difference was observed in donors' troponine T peak levels of recipients who died at 30 day after heart transplant (n ¼ 91/584, 16%) compared with recipients who did not (n ¼ 493/584, 84%) (0. cause of death and the duration of cardiac arrest. We found no difference in early and late survival rate between patients whose donors brain death was due to anoxia (n ¼ 67, 57%) and patients whose donors brain death was not due to anoxia (n ¼ 50, 43%) (89.6% vs 90.0% at 30 days, P ¼ .95; 71.8% vs 65.9% at 10 years, P ¼ .56) (Figure 3, left) . Likewise, there was no difference in survival rate at 10 years between recipients whose donors sustained a cardiac arrest 15 minutes (n ¼ 63, 54%) and recipients whose donors sustained a cardiac arrest >15 minutes (n ¼ 54, 46%) (73.6% vs 65.9%; P ¼ .68) (Figure 2, right) . In addition, there was no difference in 10-year survival between donors who sustained a cardiac arrest 10 minutes (n ¼ 49) and donors who sustained a cardiac arrest >30 minutes (n ¼ 16) (72.8% vs 81.3%; P ¼ .527).
Univariable analysis was performed with the following variables: donors age >55 years (Q4), history of cardiac arrest in donor, troponin T peak serum level >0.7 ng/mL (Q4), recipient age, preoperative ECMO, preoperative LVAD, national high urgency, postoperative ECMO, and plasmapheresis (Tables 4 and 5 ); significant variables at univariable analysis were entered in the Cox multivariable regression. Multivariable analysis showed that recipient age and postoperative ECMO were independent risk factors of 1-year mortality (Table 4) , whereas donor age>55 years (Q4), cardiac arrest, recipient age, and postoperative ECMO were independent risk factors of long-term mortality (Table 5) .
Allograft Rejection
One hundred seven (91%) recipients of the CARDþ group and 398 (85%) of the CARDÀ group had a least one endomyocardial biopsy during the follow-up. Acute cellular allograft rejection was histologically recorded in 63 (54%) recipients of the CARDþ group and in 241 (52%) recipients of the CARDÀ group. Survival free from acute allograft rejection was 31.3% in the CARDþ group and 30.4% in the CARDÀ group (P ¼ .439) (Figure 4 ).
Cardiac Allograft Vasculopathy
Three hundred eleven (67%) recipients in the CARDÀ group and 87 (74%) in the CARDþ group received a least one coronary angiography during the follow-up. CAV grade 2 was diagnosed in 7 (6%) patients of the CARDþ group and in 25 (5%) patients of the CARDÀ group and CAV grade 3 was diagnosed in 2 (2%) patients of the CARDþ group and in 15 (4%) patients of the CARDÀ group. Nine patients (8%) of the CARDþ group and 36 (8%) patients of the CARDÀ group underwent one or more percutaneous transluminal coronary angioplasty with stenting; no patient underwent coronary artery bypass grafting. Survival free from percutaneous transluminal coronary angioplasty was 85.2% in the CARDþ group and 80.2% in the CARDÀ group (P ¼ .793) (Figure 4 ).
DISCUSSION
We report a single center's heart transplantation results, focusing on the impact of cardiac arrest resuscitation in donors on recipients' survival and outcome. The first important finding of this report is that there is no difference in 30-day and 1-year survival between recipients who received an organ from a CARD and recipients who did not. We also found no difference between the 2 groups with respect to the recipient' postoperative need for ECMO for PGF or other early postoperative complications. These results are consistent with previous studies that did not show inferior outcome in recipients of heart transplantation from selected CARDs. 4, 5 The reported incidence of PGF after heart transplantation varies widely between studies, with estimates ranging between 2.3 and 26% 11 ; most of the variability can be attributed to the different definitions of PGF used by different authors. When PGF has been defined as the need for high-dose inotropes or mechanical assist devices in the immediate posttransplant period, most investigators have reported incidence rates of 10% to 20% or greater. 12 In our series, the incidence of PGF is about 30% in both groups and could be explained by the changing demographics of donors and recipients observed over the last years and the increased use of marginal donors.
The second and unexpected finding of this report is a significantly better long-term survival in recipients receiving an organ from a CARD. Possible explanations for these results are the younger age of donors who sustained a cardiac arrest in our series as well as the ischemic preconditioning effect of cardiac arrest. Donor age at transplantation is a well recognized factor having a positive effect on heart recipient survival 13, 14 ; each 1-year reduction in donor age is associated with a 1% improvement in the likelihood of 10-year survival, which means that each decade decrease in donor age produces a 10% increase in the odds of 10-year survival. 15 In addition, younger marginal donors with left ventricular dysfunction can completely recover to normal function over time before or after to heart transplantation. 16, 17 Organ ischemia due to the cardiac arrest could act as an ischemic preconditioning, thus protecting the myocardium from the subsequent ischemia/reperfusion injury occurring during transplantation. Ischemic preconditioning refers to the ability of short periods of ischemia to make the myocardium more resistant to a further and longer ischemic insult. This term was firstly introduced by Murry and colleagues, 18 who found that brief periods of ischemia accompanied by reperfusion just before sustained ischemia have multiple effects as: delay in ATP depletion, reduction in oxygen consumption, conservation of intracellular structure, and a delay or reduction of cellular necrosis due to ATP expiration, finally resulting in reduction of infarct size, despite an increase in the total ischemic period.
The strength of protection by ischemic preconditioning critically depends on the duration from the end of preconditioning ischemia to the onset of the subsequent ischemia; in fact, the protective effects of preconditioning are transient and last for less than 2 hours 19 ; however, a so-called second window of protection or delayed ischemic preconditioning has been shown to occur 24 hours after the preconditioning stimulus and lasting for about 48 hours. 20 Of note, we found no difference in recipient survival with respect to the duration of cardiac arrest in donors; these results are in contrast with previous report showing that increasing duration of cardiac arrest in donors was associated with decreased survival in recipients. 21 Despite the presence of more patients with preoperative LVAD in the CARDþ group, early and late survival in this group was not inferior to the CARDÀ group. This finding is consistent with recent reports showing an ongoing posttransplant survival improvement in patients implanted with LVAD as a bridge to transplant. 22 Finally, we found no difference in the occurrence of CAV and allograft rejection, that are well known complications affecting recipients' long-term survival after heart transplantation. 23 All these findings are of an extreme importance because actually donors with a history of cardiac arrest are considered as marginal donors and usually refused as heart donors. Our results show that donors who sustained a cardiac arrest and recuperated a normal left ventricular function at time of organ procurement can be proposed and accepted for heart transplantation to any kind of recipient. In fact in our series there was no difference between the 2 recipients groups with respect to high national urgency inscription list, meaning that marginal donors were not proposed more often to sicker or more unstable patients. The use of donors with a history of cardiac arrest is safe and may increase donors' pool, thus reducing the gap between the growing number of recipients waiting for transplantation and the ongoing shortage of organs. 24 Once stated that a short period of ischemia due to cardiac arrest does not negatively affect early and late recipients' outcome, the next step to improve organ donor pool could be to perform heart transplantation from nonheart-beating donors (NHBDs). Although only a case report of heterotopic heart transplantation 25 and small series of 3 pediatric 26 and 3 adult 27 heart transplantation from NHBD have been published, promising results have been obtained in other solid-organ transplant. [28] [29] [30] [31] The heart from NHBD sustains an obligatory hypoxic cardiac arrest and a warm ischemic period before organ procurement; subsequent reperfusion leads to intracellular Ca 2þ overload, reactive oxygen species, and an inflammatory response that result in myocardial injury. 32 Ex vivo heart perfusion has been proposed initially as a means to resuscitate hearts from cardiocirculatory death donors and expand the donor pool 33 ; further experimental studies have been performed and different perfusion techniques have been investigated to minimize organ injury and improve organ recovery. 34, 35 Limitations of the Study Clinical records of donors were provided by the French Agency for organ transplantation that guarantees for the accurateness of the information. For some donors, cardiac arrest was not witnessed, so that cardiac arrest duration refers to low-flow and the no-flow time is sometimes unknown. Data and results come from a single center and may not be applicable to other centers or countries.
CONCLUSIONS
New strategies are required to increase the number of organs available for transplantation, including expansion of donor criteria, use of NHBDs, and development of optimal preservation and perfusion techniques for the reconditioning of the heart after cardiac arrest. Myocardial ischemic injury after cardiac arrest in heart donors is of great concern, because it can result in poor graft and recipient survival. Our series shows that history of cardiac arrest resuscitation in donors with a preserved left ventricular function at time of organ procurement doesn't affect early and late outcome of heart recipients.
